RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5% Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8% Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%Net income of € 443.6 million, +6.5% Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher intere...
RECORDATI ANNUNCIA SOLIDI RISULTATI PRELIMINARI PER L’ESERCIZIO 2025: RICAVI +11,8%, EBITDA(1) +14,5%, UTILE NETTO RETTIFICATO(2) +14,5%; Ricavi netti consolidati per l’esercizio 2025 pari a € 2.618,4 milioni, +11,8% o +8,3% a perimetro omogeneo(3) e a cambi costantiEBITDA(1) pari a € 991,1 milioni, +14,5%, con un’incidenza sui ricavi netti del 37,8%Utile netto rettificato(2) pari a € 651,1 milioni, +14,5% con un’incidenza sui ricavi netti del 24,9%Utile netto pari a € 443,6 milioni, +6,5%Free cash flow(4) pari a € 558,8 milioni, +€ 23,7 milioni, grazie a un solido EBITDA, compensato in pa...
Valeo - Voting rights - January 2026 PRESS RELEASEParis, February 06, 2026 Information on the total number of voting rightsand shares forming the share capital(Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of the French Financial Markets Authority) DateIssued capitalPar valueTotal number of sharesTotal number of voting rightsTheoretical*Exercisable** January 31, 2026 € 245,607,624€ 1245,607,624275,982,567273,294,966 *In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theor...
Valeo - Déclaration des droits de vote - Janvier 2026 COMMUNIQUÉ DE PRESSEParis le 06 Février 2026 Informations relatives au nombre total de droits de voteet d’actions composant le capital social(Article L.233-8 II du Code de commerceet article 223-16 du Règlement général de l’Autorité des marchés financiers) DateCapital émisNominalNombre total d'actionsNombre total de droits de voteThéoriques*Exerçables** 31 Janvier 2026 € 245 607 624€ 1245 607 624275 982 567273 294 966 *Conformément à l’article 223-11 du Règlement général de l’AMF, le nombre total de droits de vote théoriques es...
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced that it has entered into a...
RECORDATI ANNUNCIA UNA COLLABORAZIONE STRATEGICA CON MODERNA PER SVILUPPARE E COMMERCIALIZZARE A LIVELLO GLOBALE mRNA-3927 PER IL TRATTAMENTO DELL’ACIDEMIA PROPIONICA mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari con la solida infrastruttura commerciale globale di Recordati nelle malattie rare Moderna continuerà a guidare lo sviluppo di mRNA-3927 e, in caso di approvazione, Recordati guiderà la commercializzazione a livello globale Mila...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.